Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00819871
NCT00819871CompletedNot Applicable

Association of NFKB1 -94 Polymorphism With Lung and/or Kidney Injury After Cardiac Surgery With Cardiopulmonary Bypass

Changhai Hospital1 site in 1 country105 target enrollmentStarted: May 2008Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
105
Locations
1
Primary Endpoint
lung injury and/or kidney injury after cardiac surgery with cardiopulmonary bypass
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

NFKB1 -94ins/del polymorphism has been reported to be associated with reduced promoter activity of NFKB1 and several clinical diseases, but the clinical results cannot always be replicated. Besides, mutate allele is associated with alleviated inflammation in ulcerative colitis and some tumors, but aggravated inflammation in ARDS. The clinical value of this polymorphism remains controversial. This study was performed to investigate the association of NFKB1 -94ins/delATTG polymorphism with lung and/or kidney injury after cardiac surgery with CPB.

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Chinese Han unrelated population
  • •undergoing elective cardiac surgery with CPB

Exclusion Criteria

  • •malignant tumor
  • •autoimmune disease, immunodeficiency or immunosuppressive therapy
  • •chronic renal disease (glomerular filtration rate < 60ml/(min•1.73m2)) or liver dysfunction (Child Pugh classification>A)
  • •COPD, tuberculosis or other chronic pulmonary diseases
  • •anemia with hemoglobin lower than 90mmHg
  • •bleeding disorders
  • •postoperative pericardial tamponade requiring re-operation
  • •postoperative low cardiac output syndrome or acute pulmonary edema after left cardiac failure.

Outcomes

Primary Outcomes

lung injury and/or kidney injury after cardiac surgery with cardiopulmonary bypass

Time Frame: 24h after cardiac surgery

Secondary Outcomes

  • circulating level of CRP, TNF-alpha, IL-10; APACHE Ⅱ score; duration of ICU stay and hospitalization; death in 28 days(one month after cardiac surgery)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Jia-feng Wang

M.D.

Changhai Hospital

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Influence of the NFKB1 promotor polymorphism (-94ins/delATTG) on hydrocortisone effectiveness and mortality in septic shockA41.9R57.2Sepsis, unspecifiedSeptic shock
DRKS00006111niversitätsklinikum Essen160
Completed
Not Applicable
Association of gene polymorphisms with lung function decline in patients with asthma on inhaled corticosteroidsBronchial asthma
JPRN-UMIN000002414Kyoto University Graduate School of Medicine300
Completed
Not Applicable
Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1)Legius SyndromeNeurofibromatosis Type 1
NCT00111384National Cancer Institute (NCI)313
Unknown
Phase 4
Improved Prevention of Perinatal Hepatitis B TransmissionLiver Fibrosis
NCT01133184Hadassah Medical Organization6,343
Completed
Not Applicable
Effect of Genetic Alterations Affecting the Genes Encoding the Major Enzymes of the Kynurenine Pathway on Suicidal Behavior
NCT04565834Centre Hospitalier Universitaire de Nīmes849